ASCO-GU – Keytruda strengthens its kidney cancer monopoly
Merck adds an overall survival benefit while Bristol sinks further.
Merck adds an overall survival benefit while Bristol sinks further.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.